Pfizer: TRPV1 antagonist

• Potential for safe, best-in-class analgesic
• Potential in other indications including urinary incontinence, asthma
• Exclusive worldwide collaboration with Pfizer

Certain ion channels are known to be key mediators of pain signaling. A specific family of ion channels known as transient receptor potential (TRP) ion channels, are attractive targets for drug discovery. TRPV1 (VR1 - vanilloid receptor 1) is one specific member that has compelling preclinical validation as a target for the treatment of a number of different pain states. Evotec's VR1 program is partnered with Pfizer.

In this global alliance, Evotec's and Pfizer's combined research and development teams are working together to design drugs that block VR1 and prevent it from signaling the sensation of pain. If successful, Evotec expect to have an effective, non-narcotic, non-addictive and non-steroidal analgesic to treat chronic pain, with minimal side effects.